Priorities of JV “Remedy Group” LTD are high quality and safety of products.
In accordance with the current regulatory documents (Order No. 13 of the Ministry of Health of the Republic of Uzbekistan, 5-, 6-, 10-, 15- Law of the Republic of Uzbekistan “On Medicines”, Articles 5-, 15- “On the Protection of Citizens’ Health”) and international recommendations: ICH (E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting) (E2E Pharmacovigilance Planning) (E2F Development Safety Update Report); Volume 9a of The Rules Governing Medicinal Products in the European Union Sept 2008, The International Society for Pharmacoepidemiology (ISPE): Guidelines for Good Pharmacoepidemiology Practices (GPP), a drug manufacturer must objectively and appropriately monitor the safety of its medicines. In this regard, the company operates a pharmacovigilance system.
The system includes the collection of information from all subjects of drug circulation (patients, pharmacists, doctors, etc.) in real clinical practice.
Dear colleagues and consumers!
If you have information regarding adverse reactions or lack of effectiveness of drugs produced by JV Remedy Group LLC, we suggest you fill out a message about a suspected adverse reaction or lack of effectiveness of a drug or provide the necessary information in any way convenient for you:
Authorized person responsible for pharmacovigilance at JV Remedy Group LLC:
Radjabova Munisa Akmalovna
Phone number: (99871) 226 54 65, (99890) 788 62 36
Adress: 51, Yangi Almazar str, Yangi Almazar dist., Tashkent city, Uzbekistan
All information that you provide to us is confidential and not subject to disclosure, except as otherwise provided by law.